What does it take to conduct an effective pediatric trial in diabetes in today's competitive landscape? From a lack of research infrastructure to the difficulties with determining inclusion/exclusion criteria, sponsors face many challenges in the process.
The accelerated arrival of novel vaccines and immunotherapies into the clinical space spurred the emergence of fields like personalized medicine, immune profiling and immuno-monitoring built around increasingly sophisticated testing platforms.
Hear from a panel with innovative clinical trial experience on the latest innovations in digital technologies that are changing the game in clinical trials.
Learn from entrepreneurs who've successfully launched biotech ventures to as they provide an informative and entertaining perspective on getting your biotech off the ground, the right funding model fit, how to protect your intellectual property and more.
Learn how GlaxoSmithKline gained internal buy-in to invest in a Covance technology solution to improve operational performance and accelerate decision making.
The first pivotal study in NASH was posted on clinicaltrials.gov only three years ago. Now, five Phase III trials are underway with one- and two-year Phase II data already published or communicated.
The management landscape for Type 1 diabetes (T1DM) has changed drastically since the inception of insulin replacement therapies. Today, automated insulin delivery with closed-loop technology and advances in regenerative medicine can improve glycemic control, reduce patient disease burden and decrease insulin use.
